Beacon Investment Advisory Services’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY.RT
PCM
ACM
FCM
BFS
LGP
CS
LCM
NCM
Beacon Investment Advisory Services's BMY.RT Position: Q4 2020 in Review
Beacon Investment Advisory Services sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 11,165 shares — an estimated $25K sold.
Beacon Investment Advisory Services first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $43K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.
- Beacon Investment Advisory Services reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
- Beacon Investment Advisory Services sold 11,165 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $25K.
- Beacon Investment Advisory Services first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
- Beacon Investment Advisory Services's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $43K in Q1 2020.
- 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.
Based on Beacon Investment Advisory Services's 13F filing for Q4 2020, filed 8 Feb 2021.